December 14, 2015
Imedex hosts successful Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies Conference in NYC
Three days of interactive and comprehensive education for hematologic malignancy professionals
New York, New York —World-renowned experts in the fields of multiple myeloma, chronic lymphocytic leukemia and lymphoma provided the attendees of Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies with the latest updates and guidelines for enhancing diagnostic, prognostic and therapeutic algorithms. Chaired by Drs. Morton Coleman, John P. Leonard, Ruben Niesvizky and Richard R. Furman, all faculty at Weill Cornell Medicine, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, chronic lymphocytic leukemia, myeloma and other plasma cell neoplasms for the last fifteen years.
“Imedex is proud to partner with the Congress Chairmen in bringing this successful, independent, medical educational Congress to the hematology oncology healthcare community. The Lymphoma & Myeloma Congress is dedicated to improving patient lives by providing the latest in high quality education to physicians and allied healthcare providers,” says Andrew Schutt, CEO of Imedex, LLC, the Congress organizer and accredited provider.
Over three days, the Congress hosted delegates from 44 countries, with more than 750 healthcare practitioners interested and/or involved in the treatment of patients with hematologic malignancies. Faculty and audience dialogue was encouraged, through Meet the Expert sessions, product theaters, and expert-led panel discussions spread throughout the meeting.
Current clinical challenges and considerations for the treatment and management of patients with multiple myeloma were prominently discussed including debates on the use of HDACs, the necessity of stem cell transplant and whether maintenance is required and if so, the optimal approach. Sessions in chronic lymphocytic leukemia updated the attendees on approved tyrosine kinase inhibitors, provided insight into the optimal utilization of standard of care therapies, discussed assessment of risk, and highlighted novel therapeutic strategies with promise that are currently under clinical evaluation. Presentations in lymphoma allowed the attendees to evaluate optimal therapeutic strategies for patients with diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin lymphoma and peripheral T-cell lymphoma. Included within these lectures and debates were discussion for patient selection, management of disease- and therapy-adverse events, and how to proceed after therapy failure. Additionally, presentations in the basic science sessions discussed novel biomarkers for disease prognosis, along with novel molecular pathways for targeted therapy.
“This Congress represents the largest and most comprehensive of its kind in America. Anyone attending this meeting left with a full knowledge of what is the latest and most relevant topics in lymphatic and plasma cell malignancies as imparted by the best in medicine,” says Morton Coleman, MD, Director of the Center for Lymphoma and Myeloma at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, a clinical professor of medicine at Weill Cornell Medical College, and chairmen of Lymphoma & Myeloma.
Of special note, David Roodman MD, PhD received the Joseph Michaeli Award for Contributions to Myeloma Research and Randy Gascoyne, MD, FRCPC was the recipient of the John Ultmann Award for Contributions to Lymphoma Research.
Organized by Imedex, LLC, this accredited CME meeting will again be held October 13-15, 2016 at the Waldorf Astoria Hotel. Registration is currently open and abstracts will be accepted. Visit http://www.lymphomaandmyeloma.com for more information.
Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management.
Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 97,000 live meeting attendees since 2001, Imedex truly educates the global healthcare community. At Imedex, education is the best medicine.® For more information on Imedex visit www.imedex.com.